India's leading eyewear retailer, selling prescription glasses, sunglasses and contact lenses through omnichannel stores and online.
India's leading eyewear retailer, selling prescription glasses, sunglasses and contact lenses through omnichannel stores and online.
Makes much of its own eyewear in large factories and sells it through its own stores and website, so it keeps the retailer's margin as well as the maker's and controls delivery times. Prescription glasses carry the business. Japan's Owndays, bought in 2022, gave it a base in East Asia.
In one line: India's Warby Parker/LensCrafters hybrid.
Moat: narrow (brand, scale, distribution). A vertically integrated omnichannel model (own stores plus online plus manufacturing) gives cost and reach advantages over fragmented local opticians.
Headquarters: Faridabad, India · Founded: 2010 · Employees: 21,859
Size Lenskart Solutions (LENSKART.NS) is an India Health Care company (Medical Specialties) with a market value of $13.6B, the 77th largest of 1,066 India companies the cockpit tracks. Shares closed at ₹732.10 on 18 Nov 2026.
Performance Over six months the shares gained 48.6%, against +26.2% for the median peer and +3.8% for the India market (cap-weighted) — 4th highest of 21 in its peer set.
Growth Revenue grew 35.4% over the last twelve months (peer median +4.6%); the operating margin is 9.9% (peer median 16.4%).
Valuation It trades at 137.7× forward earnings against a peer median of 20.0× (2nd most expensive of 20).
Price implies For today's price to make sense, revenue must grow about 53% a year for seven years (Req g). Recent delivered growth is +34%, so the hurdle is +20 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 3.0 points below its cost of capital (9.9% WACC).
Next results Next results expected around 3 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₹104B | ₹88.1B | ₹65.1B | ₹52.8B | ₹37.0B |
| Revenue growth | — | +35% | +23% | +43% | — |
| Gross profit | ₹37.6B | ₹27.2B | ₹21.6B | ₹17.1B | ₹14.4B |
| EBITDA | ₹22.1B | ₹18.5B | ₹8.56B | ₹5.34B | ₹1.52B |
| Net income | ₹7.80B | ₹4.94B | ₹2.96B | -₹175M | -₹680M |
| Free cash flow | n/a | ₹8.90B | ₹8.54B | ₹1.24B | -₹3.21B |
| Capital expenditure | n/a | ₹8.28B | ₹4.27B | ₹4.38B | ₹4.13B |
| Total debt | ₹34.6B | ₹31.0B | ₹25.7B | ₹21.8B | ₹23.6B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Lenskart Solutions LENSKART.NS | $13.6B | +49% | +35% | 10% | 137.7× | 53.2% |
| Titan TITAN.NS | $44.0B | +13% | +39% | 10% | 61.2× | n/a |
| Warby Parker WRBY | $3.50B | +15% | +10% | 0% | 56.2× | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | LENSKART.NS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +14.4% | +4.4% | 2nd highest of 21 |
| 6-month return | +48.6% | +26.2% | 4th highest of 21 |
| Distance from 52-week high | -4.0% | -13.5% | 2nd highest of 21 |
| Revenue growth (TTM) | +35.4% | +4.6% | 3rd highest of 21 |
| Operating margin | 9.9% | 16.4% | 7th lowest of 21 |
| Forward P/E | 137.7× | 20.0× | 2nd most expensive of 20 |
| Growth the price implies (Req g, 7 yrs) | 53.2% | 10.6% | most demanding of 18 |
| Growth delivered (Del g) | +33.5% | +6.7% | highest of 18 |
| Hurdle (Req g minus delivered) | +19.7 pp | +4.2 pp | 3rd most demanding of 18 |
| ROIC minus cost of capital | -3.0 pp | +0.9 pp | 8th lowest of 21 |
| EV / EBITDA | 58.3× | 14.0× | most expensive of 18 |
| Net debt / EBITDA | 0.7× | 1.8× | 7th least indebted of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Lenskart Solutions LENSKART.NS | India | $13.6B | +49% | +35% | 10% | 137.7× | 53.2% | +33.5% |
| Baxter International BAX | United States | $13.5B | +39% | +5% | 6% | 12.7× | 13.4% | -0.7% |
| Glaukos GKOS | United States | $13.8B | +62% | +47% | -9% | 161.5× | n/a | n/a |
| Shanghai United Imaging Healthcare 688271.SS | China | $14.4B | +4% | +27% | 9% | 45.7× | n/a | n/a |
| Olympus 7733.T | Japan | $12.7B | +5% | +9% | 18% | 18.7× | -6.5% | +6.7% |
| Penumbra PEN | United States | $12.6B | -2% | +17% | 12% | 55.7× | 30.7% | +20.2% |
| Smith & Nephew SN..L | United Kingdom | $12.6B | +1% | +2% | 17% | 14.2× | 11.1% | +5.6% |
| bioMerieux BIM.PA | France | $11.8B | +26% | -3% | 15% | 20.2× | 8.6% | +5.5% |
| Align Technology ALGN | United States | $11.6B | 0% | +4% | 19% | 13.8× | 13.1% | +10.3% |
| Cooper Companies (The) COO | United States | $11.6B | -2% | +5% | 19% | 13.4× | 9.4% | +11.0% |
| Coloplast A/S COLO-B.CO | Denmark | $16.6B | +24% | +4% | 25% | 20.0× | -2.1% | +8.3% |
| Revvity RVTY | United States | $17.0B | +61% | +5% | 16% | 26.2× | 26.4% | -5.5% |
| Avantor AVTR | United States | $10.4B | +95% | +1% | 8% | 17.5× | 16.4% | +0.5% |
| Demant A/S DEMANT.CO | Denmark | $10.4B | +39% | +10% | 18% | 23.2× | 5.8% | +9.8% |
| Qiagen QGEN | United States | $10.2B | +41% | +2% | 25% | 19.5× | 8.6% | +2.2% |
| Bio-Rad Laboratories BIO | United States | $10.1B | +29% | +1% | 9% | 34.6× | 26.0% | +0.3% |
| Insulet PODD | United States | $9.71B | -11% | +26% | 18% | 18.6× | 10.6% | +24.5% |
| Bruker BRKR | United States | $9.66B | +43% | +2% | 10% | 27.0× | 25.4% | +11.6% |
| Zimmer Biomet ZBH | United States | $19.6B | +21% | +7% | 16% | 11.7× | 7.4% | +3.2% |
| Guardant Health GH | United States | $19.6B | +26% | +42% | -39% | n/a | n/a | n/a |
| Sonova SOON.SW | Switzerland | $19.8B | +40% | -6% | 23% | 25.3× | 6.0% | +6.7% |